Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma

A Mount Sinai-Led Study Shows Early Success of a Novel Drug in Treating a Rare and Chronic Blood Cancer

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

Mount Sinai’s Staten Island Cancer Center Moves to New Site

Adding Immunotherapy to Chemotherapy Regimen Improves Survival in Metastatic Bladder Cancer Patients

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

FDA dense breast guideline shouldn't trigger 'knee-jerk' reactions, Mount Sinai surgeon says

Deborah Doroshow, MD, on the Disappointments Uncovered About Inpatient Immunotherapy

The Genetics of Multiple Myeloma: Expert Perspectives

Woman, 36, recalls being diagnosed with cervical cancer while pregnant with 1st child

Chari Spotlights Efficacy of Talquetamab and Next Steps for Exploration in R/R Multiple Myeloma